Bio & Pharma
Celltrion Pharm gets GMP certification from Japan
The PFS facility in Cheongju is certified by regulatory authorities in five countries: S.Korea, EU, US, Brazil, and Japan
By Sep 27, 2023 (Gmt+09:00)
1
Min read
Most Read
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
NPS to hike risky asset purchases under simplified allocation system
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
S.Korea's LS Materials set to boost earnings ahead of IPO process
UAE to invest up to $1 bn in S.Korean ventures
Celltrion Pharm Inc. announced on Wednesday that its pre-filled syringe (PFS) production facility in Cheongju, North Chungcheong Province has obtained good manufacturing practice (GMP) certification from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
According to the company, PMDA investigated conformity on Yuflyma’s PFS production facility and made an approval decision. Yuflyma is a biosimilar of Humira, an autoimmune disease treatment developed by AbbVie, with the active ingredient Adalimumab.
Celltrion Pharm has got GMP certification from regulatory authorities in five countries, including South Korea, the European Union, the US, Brazil, and Japan for its Cheongju plant's PFS production facility.
"We have plans to continue revenue growth by gradually expanding PFS dosage form production, targeting major global markets, including the domestic market," a Celltrion Pharm source said.
Celltrion Pharm's PFS production facility in Cheongju plant is a three-story building with a total floor area of 2,315 square meters. It is capable of producing pharmaceuticals in three types of PFS: auto-injectors, PFS, and PFS-S (with safety devices).
Write to Ye-Na Kim at yena@hankyung.com
More to Read
-
Bio & PharmaCelltrion signs largest-ever quarterly deal with global sales affiliate
Sep 25, 2023 (Gmt+09:00)
2 Min read -
KOREA Investment Week 2023Celltrion builds clinical data bank for new biosimilars
Sep 12, 2023 (Gmt+09:00)
2 Min read
Comment 0
LOG IN